Roivant Discovery

Roivant Discovery is the internal drug discovery engine of Roivant, focused on discovering and designing new therapeutics rather than serving as a standalone late-stage development company. The organization combines physics-based simulation, machine learning, translational informatics, chemical biology, and proteomics to identify and optimize novel programs, including small molecules and induced-proximity approaches such as degraders. It appears to function as a strategic discovery unit within the broader Roivant family rather than as an independently listed operating company with its own public pipeline disclosures. Roivant Discovery supports target selection, biomarker identification, and early program generation across multiple therapeutic areas and modalities. Its positioning is best understood as a platform-enabled preclinical research organization embedded inside Roivant's biotech creation model.